X4 Pharmaceuticals (XFOR) Invested Capital (2018 - 2025)
X4 Pharmaceuticals (XFOR) has disclosed Invested Capital for 8 consecutive years, with $136.6 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Invested Capital rose 1.48% year-over-year to $136.6 million, compared with a TTM value of $136.6 million through Sep 2025, up 1.48%, and an annual FY2024 reading of $97.1 million, down 8.44% over the prior year.
- Invested Capital was $136.6 million for Q3 2025 at X4 Pharmaceuticals, up from $79.0 million in the prior quarter.
- Across five years, Invested Capital topped out at $169.5 million in Q2 2024 and bottomed at $56.0 million in Q1 2024.
- Average Invested Capital over 5 years is $104.5 million, with a median of $100.0 million recorded in 2023.
- Peak annual rise in Invested Capital hit 74.79% in 2025, while the deepest fall reached 53.4% in 2025.
- Year by year, Invested Capital stood at $96.9 million in 2021, then increased by 9.95% to $106.6 million in 2022, then dropped by 0.42% to $106.1 million in 2023, then fell by 8.44% to $97.1 million in 2024, then soared by 40.63% to $136.6 million in 2025.
- Business Quant data shows Invested Capital for XFOR at $136.6 million in Q3 2025, $79.0 million in Q2 2025, and $97.9 million in Q1 2025.